核PTENは,APC-CDH1腫瘍抑制複合体を,フォスファタゼから独立した方法で調節する
Min Sup Song1, Arkaitz Carracedo, Leonardo Salmena
1Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Cell
|January 19, 2011
まとめ
核PTENタンパク質はAPC/Cと相互作用し,その腫瘍抑制活性を強化する. この発見は,PTEN PTENを説明する.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- 細胞生物学 細胞生物学
背景:
- PTEN (フォスファタゼとテンシンホモログ) は,PI3K/AKT経路に反対する重要な腫瘍抑制遺伝子です.
- PTENの核の局所化は,その腫瘍抑制機能に不可欠ですが,その特定の核の役割はよく理解されていません.
研究 の 目的:
- PTENの核機能と腫瘍抑制におけるその役割を解明する.
- 核PTENとアナフェーズ促進複合体/サイクロソーム (APC/C) 複合体の相互作用を調査する.
主な方法:
- 核PTENとAPC/Cコンポーネント (例えばCDH1) の相互作用を調査した.
- APC/C機能に対するPTEN核排斥とフォスファタゼ不活性化の影響を評価した.
- 分析されたPTEN変異および無状態のAPC/C標的 (PLK1,オーロラキナーゼ) の阻害剤に対する感受性.
主要な成果:
- 核PTENは,APC/Cと直接相互作用し,CDH1との結合を促進し,APC-CDH1複合体の活性を強化する.
- PTENのフォスファタゼ活性ではなく,PTENの核排除がAPC-CDH1の機能を損なっており,PTENの喪失に対する老化反応を説明しています.
- PTENの変異状態と無状態は,PLK1およびオーロラキナーゼ阻害剤に対する異なる感受性を示す.
結論:
- 核PTENは,APC-CDH1複合体の重要な調節体として機能し,腫瘍抑制作用に貢献します.
- このメカニズムは,細胞老化におけるPTENの役割と,触媒的に不活性なPTENの腫瘍抑制活性を説明する.
- 発見は,がん患者の階層化と,PTEN状態に基づいて標的治療の最適化のための基礎を提供します.
関連する概念動画
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
01:19Allosteric Proteins-ATCase
4.8K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
4.8K
00:50Anaphase Promoting Complex
2.5K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
2.5K